Lorcaserin and pimavanserin: Emerging selectivity of serotonin receptor subtype-targeted drugs

Journal of Clinical Investigation

Volumn 123, Issue 12, 2013, Pages 4986-4991

  Meltzer, Herbert Y ^a   Roth, Bryan L ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; AZD 3783; BUSPIRONE; CLOZAPINE; FENFLURAMINE; GRANISETRON; HALOPERIDOL; KETANSERIN; LEVODOPA; LORCASERIN; METFORMIN; METOCLOPRAMIDE; NORFENFLURAMINE; OLANZAPINE; ONDANSETRON; PHENTERMINE; PIMAVANSERIN; PLACEBO; RISPERIDONE; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; SULFONYLUREA; SUMATRIPTAN; TANDOSPIRONE; TERGURIDE; TROPISETRON; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CALORIC INTAKE; CHEMOTHERAPY INDUCED NAUSEA; COGNITIVE DEFECT; COMPARATIVE STUDY; DEPRESSION; DIET; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EATING DISORDER; ECHOCARDIOGRAPHY; ENERGY EXPENDITURE; EXERCISE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL MOTILITY DISORDER; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INVERSE AGONISM; MAJOR DEPRESSION; MIGRAINE; MOLECULAR CLONING; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL COUNSELING; OBESITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; PULMONARY HYPERTENSION; REVIEW; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SINUSITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

BENZAZEPINES; DIABETES MELLITUS, TYPE 2; HEART VALVE DISEASES; HUMANS; MOLECULAR STRUCTURE; OBESITY; PARKINSON DISEASE; PIPERIDINES; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; UREA;

EID: 84890031883     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70678     Document Type: Review

References (81)

1. Rapport MM, Green AA, Page IH. Crystalline serotonin. Science. 1948;108(2804):329-330
2. Wooley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci U S A. 1954;40(4):228-231
3. Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptors. Br J Pharmacol Chemother. 1957; 12(3):323-328
4. Dixon RA, et al. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature. 1986;321(6065):75-79
5. Gozlan H, El Mestikawy S, Pichat L, Glowinski J, Hamon M. Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT. Nature. 1983;305(5930):140-142
6. Kobilka FK, et al. An intron-less gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature. 987;329(6134):75-79
7. Fargin A, Raymond JR, Lohse MJ, Kobilka BK, Caron MG, Lefkowitz RJ. The genomic clone G-21 which resembles a β-adrenergic receptor sequence encodes the 5-HT1A receptor. Nature. 1988; 335(6188):358-360
8. Kroeze WK, Roth BL. The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biol Psychiatry. 1998; 44(11):1128-1142
9. Kroeze WK, Kristiansen K, Roth BL. Molecular biology of serotonin receptors structure and function at the molecular level. Curr Top Med Chem. 2002; 2(6):507-528
10. Middlemiss DN. Stereoselective blockade at [3H]5-HT binding sites and at the 5-HT autoreceptor by propranolol. Eur J Pharmacol. 1984; 101(3-4):289-293
11. Leonhardt S, Herrick-Davis K, Titeler M. Detection of a novel serotonin receptor subtype (5-HT1E) in human brain: interaction with a GTP-binding protein. J Neurochem. 1989;53(2):465-471
12. Leysen JE, Niemegeers CJ, Tollenaere JP, Laduron PM. Serotonergic component of neuroleptic receptors. Nature. 1978;272(5649):168-171
13. Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM. [3H]-ketanserin (R 41 468) a selective 3H-ligand for serotonin2 receptor binding sites. Mol Pharmacol. 1982;21(2):301-314
14. Conn PJ, Sanders-Bush E, Hoffman BJ, Hartig PR. A unique serotonin receptor in choroid plexus is linked to phosphatidylinositol turnover. Proc Natl Acad Sci U S A. 1986;83(11):4086-4088
15. Pazos A, Hoyer D, Palacios JM. The binding of serotonergic ligands to the procine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol. 1984;106(3):539-546
16. Dumuis A, Sebben M, Bockaert J. The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol. 1989;340(4):403-410
17. Bockaert J, Sebben M, Dumuis A. Pharmacological characterization of 5-hydroxytryptamine4(5-HT4) receptors positively coupled to adenylate cyclase in adult guinea pig hippocampal membranes: effect of substituted benzamide derivatives. Mol Pharmacol. 1990;37(3):408-411
18. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355-366
19. Wang C, et al. Structural basis for molecular recognition at serotonin receptors. Science. 2013; 340(6132):610-614
20. Roth BL, Nakaki T, Chuang DM, Costa E. Aortic recognition sites for serotonin (5HT) are coupled to phospholipase C and modulate phosphatidylinositol turnover. Neuropharmacology. 1984; 23(10):1223-1225
21. Conn PJ, Sanders-Bush E. Selective 5-HT2 antagonists inhibit serotonin-stimulated phosphatidylinositol metabolism in cerebral cortex. Neuropharmacology. 1984;23(8):993-996
22. Roth BL, Nakaki T, Chuang DM, Costa E. 5-Hydroxytryptamine2 receptors coupled to phospholipase C in rat aorta: modulation of phosphoinositide turnover by phorbol ester. J Pharmacol Exp Ther. 1986;238(2):480-485
23. Roth BL, Ciaranello RD, Meltzer HY. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther. 1992;260(3):1361-1365
24. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004;3(4):353-359
25. Roth BL, Willins DL, Kristiansen K, Kroeze WK. 5-Hydroxytryptamine2- family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther. 1998;79(3):231-257
26. Roth B, Willins D, Kristiansen K, Kroeze W. Activation is hallucinogenic and antagonism is therapeutic: role of 5-HT2A receptors in atypical antipsychotic drug actions. The Neuroscientist. 1999; 5:254-262
27. Roth BL. Drugs and valvular heart disease. N Engl J Med. 2007;356(1):6-9.
28. Huang XP, et al. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine (2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol. 2009; 76(4):710-722
29. Wacker D, et al. Structural features for functional selectivity at serotonin receptors. Science. 2013; 340(6132):615-619
30. Roth BL, et al. Binding of typical and atypical antipsychotic agents to 5- hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994;268(3):1403-1410
31. Weiner DM, et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther. 2001;299(1):268-276
32. Rauser L, Savage JE, Meltzer HY, Roth BL. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine (2C) receptor. J Pharmacol Exp Ther. 2001; 299(1):83-89
33. Kenakin T. Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol. 2002;42:349-379
34. Keiser MJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462(7270):175-181
35. Starkstein SE, Brockman S, Hayhow BD. Psychiatric syndromes in Parkinson's disease. Curr Opin Psychiatry. 2012;25(6):468-472
36. Blundell JE. Serotonin and appetite. Neuropharmacology. 1984;23(12B):1537-1551
37. Tecott LH, et al. Eating disorder and epilepsy in micelacking 5-HT2c serotonin receptors. Nature. 1995; 374(6522):542-546
38. Vickers SP, Clifton PG, Dourish CT, Tecott LH. Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacology (Berl). 1999;143(3):309-314
39. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med. 1984; 144(6):1143-1148
40. Connolly HM, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997; 337(9):581-588
41. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary ypertension and fenfluramine use. Br Heart J. 1993;70(6):537-541
42. Rothman RB, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000; 102(23):2836-2841
43. Launay JM, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med. 2002;8(10):1129-1135
44. Fitzgerald LW, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000; 57(1):75-81
45. Thomsen WJ, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325(2):577-587
46. Smith SR, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245-256
47. Fidler MC, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067-3077
48. Martin CK, et al. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2010;96(3):837-845
49. O'Neil PM, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426-1436
50. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001;158(3):360-369
51. Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 1976; 2(1):19-76
52. Angst J, Bemte D, Berner P, Heimann H, Helmchen H, Hippius H. Das klinische wirkungsbild von clozapine. Pharmacopsychiaties. 1971;4:201-221
53. Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses. 2012;6(3):134-144
54. Meltzer HY, Matsubara S, Lee J-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251(1):238-246
55. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res. 2008;172:177-197
56. Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64:393-406
57. Kroeze WK, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519-526
58. Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology. 1995;12(1):39-45
59. Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebocontrolled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry. 2004;161(6):975-984
60. Vanover KE, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin- 4-yl)-N′-(4-(2- methylpropyloxy)phen ylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine (2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006;317(2):910-918
61. Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY. ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl). 2005;183(2):144-153
62. Fribourg M, et al. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell. 2011; 147(5):1011-1023
63. Meltzer HY, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology. 2010;35(4):881-892
64. Cummings JL, et al. Antipsychotic efficacy and motor tolerability in a Phase III placebo controlled study of pimavansserin in patients with Parkinson's disease psychosis. Neurology. 2013;80(19):e530
65. ACADIA Pharmaceuticals, Inc. Web Site. Pimavanserin overview. http://www.acadia-pharm. com/pipeline/pimavanserin.htm. Accessed October 30, 2013
66. Price DL, Bonhaus DW, McFarland K. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. Behav Pharmacol. 2012; 23(4):426-433
67. Meltzer HY, et al. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res. 2012;141(2-3):144-152
68. Gardell LR, et al. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J Pharmacol Exp Ther. 2007;322(2):862-870
69. Snigdha S, et al. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2009; 332(2):622-631
70. Luttrell LM, et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science. 1999;283(5402):655-661
71. Beaulieu JM, et al. A β-arrestin 2 signaling complex mediates lithium action on behavior. Cell. 2008; 132(1):125-136
72. Noma T, et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest. 2007; 117(9):2445-2458
73. Walters RW, et al. β-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest. 2009; 119(5):1312-1321
74. Allen JA, et al. Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A. 2011;108(45):18488-18493
75. Allen JA, Roth BL. Strategies to discover unexpected targets for drugs active at g protein-coupled receptors. Annu Rev Pharmacol Toxicol. 2011;51:117-144
76. Yadav PN, Kroeze WK, Farrell MS, Roth BL. Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther. 2011;339(1):99-105
77. Sumiyoshi T, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry. 2001;158(10):1722-1725
78. Zhang M, et al. Preclinical pharmacology and pharmacokinetics of AZD3783, a selective 5-hydroxytryptamine 1B receptor antagonist. J Pharmacol Exp Ther. 2011;339(2):567-578
79. Brodney MA, et al. Identification of multiple 5-HT(4) partial agonist clinical andidates for the treatment of Alzheimer's disease. J Med Chem. 2012; 55(21):9240-9254
80. Maher-Edwards G, et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr Alzheimer Res. 2010;7(5):374-385
81. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl). 2009;205(1):119-128